VYNE Therapeutics Inc. (VYNE) has a negative trailing P/E of -1.0, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -101.35%.
Criteria proven by this page:
Overall SharesGrow Score: 53/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -44.5 | -0.72 | -21.25 | 928.02 | - |
| 2017 | -20.3 | -0.17 | -10.37 | 129.04 | - |
| 2018 | -1.7 | -0.03 | 0.68 | 8.39 | - |
| 2019 | -2.2 | 0.18 | 2.30 | 355.49 | - |
| 2020 | -0.8 | 0.16 | 5.46 | 9.76 | - |
| 2021 | -0.7 | 0.01 | 1.08 | 56.38 | - |
| 2022 | -0.4 | 0.01 | 0.28 | 18.03 | - |
| 2023 | -0.8 | 0.01 | 0.27 | 56.45 | - |
| 2024 | -3.6 | 0.05 | 2.74 | 284.78 | - |
| 2025 | -0.9 | 0.03 | 0.89 | 43.53 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-87.78 | $674K | $-14.07M | -2087.2% |
| 2017 | $-101.65 | $4.58M | $-29.08M | -634.6% |
| 2018 | $-170.94 | $10.64M | $-51.45M | -483.5% |
| 2019 | $-149.48 | $443K | $-70.46M | -15906.1% |
| 2020 | $-141.90 | $20.99M | $-255.57M | -1217.4% |
| 2021 | $-25.65 | $14.76M | $-73.33M | -497% |
| 2022 | $-10.65 | $477K | $-33.95M | -7116.4% |
| 2023 | $-2.77 | $424K | $-28.45M | -6710.4% |
| 2024 | $-0.93 | $501K | $-39.83M | -7950.9% |
| 2025 | $-0.62 | $570K | $-26.48M | -4646.1% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.81 | $-1.04 – $-0.56 | $350K | $350K – $350K | 1 |
| 2027 | $-0.64 | $-0.64 – $-0.64 | $10.25M | $10.25M – $10.25M | 1 |
| 2028 | $-0.64 | $-0.64 – $-0.64 | $13.6M | $13.6M – $13.6M | 1 |
| 2029 | $-2.65 | $-2.65 – $-2.65 | $50M | $50M – $50M | 1 |
